Pfizer’s Sickle Cell Drug Candidates Unaffected by Oxbryta Withdrawal

In what is a major development in the pharma space, Pfizer Inc. said that its set of upcoming sickle cell drug candidates remain unaffected by the recent withdrawal of Oxbryta, another medication pointed toward treating the same condition. An update comes amidst increased scrutiny on drug efficacy and regulatory compliance.

Continue reading